Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy is a paper indexed in PICO Portal from OpenAlex.
How many citations does Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy have?
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy has 99 citations in the OpenAlex counts PICO Portal stores.
When was Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy published?
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy has 2012 year in the PICO Portal index.
What is the open-access status of Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy?
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy has green oa status in the PICO Portal index.
What is the DOI of Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy?
The DOI for Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy is on the source record.
What is the PMID of Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy?
The PMID for Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy is on the source record.
What is the OpenAlex record for Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy?
The OpenAlex for Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy is on the source record.